SCHEMBL6834522

SCHEMBL6834522

CCOC(=O)C=C(c1cccnc1)c1cccc(NS(=O)(=O)c2ccc(OCC)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.60
PKM P14618 2/20 0.53
GAA P10253 2/20 0.53
TBXA2R P21731 1/20 0.52
TBXAS1 P24557 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.51
HTT P42858 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ALOX15 P16050 2/20 0.50
HPGD P15428 1/20 0.50
OPRM1 P35372 1/20 0.50
OPRD1 P41143 1/20 0.50
MAPT P10636 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6834521 1.00 LMNA (0.60) LMNAPKMGAATBXA2RTBXAS1
SCHEMBL6834520 1.00 LMNA (0.60) LMNAPKMGAATBXA2RTBXAS1
SCHEMBL6836008 0.93 TCF4 (0.55) LMNAPKMGAATBXA2RTBXAS1
SCHEMBL6836006 0.93 TCF4 (0.55) LMNAPKMGAATBXA2RTBXAS1
SCHEMBL6836003 0.93 TCF4 (0.55) LMNAPKMGAATBXA2RTBXAS1
SCHEMBL6834369 0.84 TCF4 (0.65) LMNAPKMGAASMN1; SMN2HTT
SCHEMBL6830949 0.81 TCF4 (0.61) LMNAPKMGAASMN1; SMN2HTT
SCHEMBL6830952 0.81 TCF4 (0.61) LMNAPKMGAASMN1; SMN2HTT
SCHEMBL6834624 0.79 TCF4 (0.58) LMNAGAATBXA2RTBXAS1SMN1; SMN2
SCHEMBL6834627 0.79 TCF4 (0.58) LMNAGAATBXA2RTBXAS1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040029928-A1 Novel propenohydroxamic acid derivatives WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029928-A1 Novel propenohydroxamic acid derivatives TNF, SI, HDGF LMNA 1537/4885PKM 3077/4885GAA 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.